Lamotrigine Extended-Release Tablets, USP, 200 mg, 30 tablets per bottle, Rx Only, Manufactured i...
FDA Drug Recall #D-1204-2018 — Class II — September 11, 2018
Recall Summary
| Recall Number | D-1204-2018 |
| Classification | Class II — Moderate risk |
| Date Initiated | September 11, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Torrent Pharma Inc. |
| Location | Kalamazoo, MI |
| Product Type | Drugs |
| Quantity | 15,384 30-count bottles |
Product Description
Lamotrigine Extended-Release Tablets, USP, 200 mg, 30 tablets per bottle, Rx Only, Manufactured in INDIA, For: TORRENT PHARMA INC., 150 Allen Road, Suite 102, Basking Ridge, NJ 07920. NDC: 13668-342-30
Reason for Recall
Failed Dissolution Specifications: Out of Specification for Dissolution test (Buffer Stage) at the 5-hour time point during stability testing.
Distribution Pattern
Nationwide USA
Lot / Code Information
Lot: BFR5D002 EXP 11-2019
Other Recalls from Torrent Pharma Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0455-2025 | Class II | Fluoxetine Tablets, USP, 20 mg, 30-count bottl... | May 27, 2025 |
| D-0456-2025 | Class II | Fluoxetine Tablets, USP, 20 mg, 28-count Carton... | May 27, 2025 |
| D-0365-2022 | Class II | Carbamazepine Tablets, USP 200 mg 100 Tablets R... | Dec 2, 2021 |
| D-0285-2022 | Class III | Telmisartan and Hydrochlorothiazide Tablets, US... | Dec 1, 2021 |
| D-1317-2020 | Class II | Carbamazepine Tablets, USP 200 mg, packaged in ... | May 11, 2020 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.